摘要
目的:了解多药耐药MDR基因在卵巢癌中的表达及表达产物P-糖蛋白(P-gp)与化疗耐药性的关系。方法:用免疫组化法测定卵巢癌54例手术切除肿瘤组织P-gp的表达情况,分析其与临床、病理及化疗效果的关系。结果:P-gp表达阳性者24例,占44.4%,P-gp表达与临床分期、病理分级、术后残余瘤大小无关。P-gp阳性与阴性者所接受的化疗无差异。术前用过与MDR有关药物化疗者,P-gp阳性率为69.2%,高于未化疗者(36.6%)。P-gp阳性者化疗近期疗效差,化疗有效率为47.1%,低于P-gp阴性者的81.8%,但两组预后无差异。结论:测定P-gp表达有助于预测肿瘤的耐药性及指导化疗药物的选择。P-gp表达是化疗耐药原因之一。
Objectives: To determine P glycoprotein expression in epithelial ovarian cancers and to analyze the relation between P glycoprotein and drug resistance in the chemotherapy of ovarian cancers. Methods:Immunohistochemical staining of P glycoprotein expression was performed on specimens from 54 epithelial ovarian cancer patients,and the patients were followed up.The relation of P glycoprotien expression to clinicopathologic features,response to chemotherapy,and prognosis of these patients were analyzed. Results: Twenty four out of 54 tumors expressed P glycoprotein(44.%),P glycoprotein expression was not related to other prognostic factors such as stage,grade,histologic types and residual tumor size,and the chemotherapy was not different in the patients with positive or negative P glycoprotein expression.The positive rate of P glycoprotein expression was 69.2% in the tumors treated with agents related to multidrug resistance,and 36.6% in previously untreated tumors.The reponse rate to chemotherapy was higher in the group with negative P glycoprotein expression(81.8%)than that in the group with positive P glycoprotein expression(47.1%), P <0.05.P glycoprotein expression was not associated with prognosis of these patients Conclusions:The positive staining for P glycoprotein is one of the determinants involved in the chemoresistance of ovarian cancer,the determination of P glycoprotein can be helpful in the prediction of cellular resistance to chemotherapy,and in the choose of antitumor agents.
出处
《现代妇产科进展》
CSCD
1997年第2期104-106,共3页
Progress in Obstetrics and Gynecology